The IPO market is starting to heat up again.
And while no unicorns have filed to go public, at least two healthcare and biopharma companies with hedge fund investors priced their deals earlier this week.
For example, Black Diamond Therapeutics said in a regulatory filing that it plans to offer 8.9
